-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-508012-35-00
5
2024-10-02
Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-503708-10-00
5
2024-02-20
Locally advanced or metastatic breast cancer
-
2022-502980-39-00
5
2024-01-25
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-520108-25-00
4
2025-11-05
Non-small cell lung cancer (NSCLC)
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-513165-39-00
5
2024-11-11
Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS
-
2024-513160-25-00
5
2024-10-30
Melanoma and Non-small-cell lung cancer
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma